Sagimet Biosciences Reports Q2 Financials, Denifanstat Meets Endpoints in Phase 3 Trial

• Sagimet Biosciences reports Q2 2025 financial results • Denifanstat meets endpoints in Phase 3 acne trial in China • Initiated Phase 1 trial for FASN inhibitor TVB-3567 • Phase 1 trial for denifanstat and resmetirom PK expected in 2H 2025 • Data readout expected in 1H 2026

Sagimet Biosciences Inc. (SGMT), a biopharmaceutical company specializing in novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, has reported its financial results for the quarter ended June 30, 2025. The company's press release, issued on August 13, 2025, provides key insights into its financial performance and ongoing clinical trials [1].

Financial Performance

For the second quarter of 2025, Sagimet reported a net loss of $10.4 million, up from $14.7 million in the first half of 2024. The company's cash and equivalents stood at $135.5 million as of June 30, 2025. Research and development expenses increased to $22.6 million for the first half of 2025, reflecting the company's intensified clinical activities [2].

Clinical Advancements

One of the standout achievements in Q2 2025 was the successful completion of the Phase 3 clinical trial for denifanstat in acne treatment by license partner Ascletis in China. The trial met all primary and secondary endpoints, showing a 33.2% treatment success rate versus 14.6% for placebo. Denifanstat also demonstrated significant reductions in total lesion count compared to placebo [2].

Sagimet has initiated a Phase 1 clinical trial for its second FASN inhibitor, TVB-3567, for acne treatment in the United States. Additionally, the company plans to start a Phase 1 clinical trial to evaluate the pharmacokinetics (PK) and tolerability of a combination of denifanstat and resmetirom for MASH treatment in the second half of 2025. Data readout for this trial is expected in the first half of 2026 [2].

Pipeline Diversification and Strategic Combination

Sagimet's strategic focus on acne and MASH provides a dual approach to targeting dysfunctional metabolic pathways. The company's recent clinical advancements underscore the potential of its FASN inhibitor platform, validating its scientific approach and opening potential commercialization pathways in large markets [2].

Conclusion

Sagimet Biosciences' Q2 2025 results highlight the company's significant progress in advancing its differentiated therapeutics. The successful Phase 3 trial for denifanstat in acne, coupled with the initiation of new clinical trials, positions the company favorably for future growth. Despite the ongoing net loss, the company's strong cash position and pipeline diversification indicate a promising outlook for investors.

References

[1] https://www.stocktitan.net/sec-filings/SGMT/8-k-sagimet-biosciences-inc-series-a-reports-material-event-cd2ae4397e94.html

[2] https://www.stocktitan.net/news/SGMT/sagimet-biosciences-reports-second-quarter-2025-financial-results-u0q1nfpgryeu.html